Danco Laboratories and DOJ ask for US Supreme Court Action on Conflicting Mifepristone Rulings
April 14, 2023
Both the US Department of Justice (DOJ) and the mifepristone distributor Danco Laboratories have called upon the US Supreme Court to act quickly to hold back the effects of dueling federal court cases regarding the drug. The Fifth Circuit Court of Appeals temporarily paused last week’s ruling that mifepristone, a key drug used in the abortion pill, was inappropriately approved. Although mifepristone can stay on the market for now, expanded access to the drug would be cut, putting manufacturers and the FDA in conflict with another ruling last Friday.
According to Danco, “FDA is simultaneously under court order from the Eastern District of Washington enjoining it from changing any aspect of its regulation and approval of mifepristone in the 17 States plus the District of Columbia that are plaintiffs to that suit. The result is an untenable limbo, for Danco, for providers, for women, and for health care systems all trying to navigate these uncharted waters—and all after Plaintiffs waited years and years before claiming irreparable injury and a need for an emergency injunction voiding the decades-long status quo.”
To read more, click here.
(Source: Endpoints News, April 14th, 2023)
